Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone washout and AVONEX rechallenge in relapsing-remitting multiple sclerosis with neutralising antibodies
ACTRN12605000657628Phase 4Recruiting
- Sponsor
- Biogen
- Start
- Feb 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of interferon beta-1a and methylprednisolone in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Return of bioavailability of AVONEX. Started Feb 2004; status: recruiting.
02
Drugs
interferon beta-1amethylprednisolone
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12605000657628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000657628.